As of close of business last night, AbCellera Biologics Inc’s stock clocked out at $5.12, up 3.43% from its previous closing price of $4.95. In other words, the price has increased by $+0.17 from its previous closing price. On the day, 2577813 shares were traded.
Ratios:
To gain a deeper understanding of ABCL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.32 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 26 when Thermopylae Holdings Ltd. bought 153,000 shares for $6.52 per share. The transaction valued at 997,728 led to the insider holds 56,012,493 shares of the business.
Booth Andrew bought 14,500 shares of ABCL for $99,325 on May 26. The Chief Financial Officer now owns 153,000 shares after completing the transaction at $6.85 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1.50B and an Enterprise Value of 815.84M. For the stock, the TTM Price-to-Sale (P/S) ratio is 39.42 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at 21.46 whereas that against EBITDA is -4.25.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $8.63, while it has fallen to a 52-week low of $3.87. The 50-Day Moving Average of the stock is 5.37, while the 200-Day Moving Average is calculated to be 5.60.
Shares Statistics:
It appears that ABCL traded 1.57M shares on average per day over the past three months and 1.9M shares per day over the past ten days. A total of 290.82M shares are outstanding, with a floating share count of 200.22M. Insiders hold about 31.61% of the company’s shares, while institutions hold 38.38% stake in the company. Shares short for ABCL as of Jan 31, 2024 were 24.49M with a Short Ratio of 15.55, compared to 25.58M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.44% and a Short% of Float of 11.75%.
Earnings Estimates
As of right now, 8 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.16 for the current quarter, with a high estimate of -$0.12 and a low estimate of -$0.25, while EPS last year was -$0.14. The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.1 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.48 and -$1.01 for the fiscal current year, implying an average EPS of -$0.62. EPS for the following year is -$0.68, with 7 analysts recommending between -$0.45 and -$0.99.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $11.08M. It ranges from a high estimate of $18.29M to a low estimate of $9.22M. As of the current estimate, AbCellera Biologics Inc’s year-ago sales were $12.19M, an estimated decrease of -9.10% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $11.45M, an increase of 13.90% over than the figure of -$9.10% in the same quarter last year. There is a high estimate of $17.36M for the next quarter, whereas the lowest estimate is $9.22M.
A total of 10 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $77.46M, while the lowest revenue estimate was $36.9M, resulting in an average revenue estimate of $50.65M. In the same quarter a year ago, actual revenue was $38.02M, up 33.20% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $71.89M in the next fiscal year. The high estimate is $117.86M and the low estimate is $50M. The average revenue growth estimate for next year is up 41.90% from the average revenue estimate for this year.
